Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. (Nasdaq: BIIB) is a pioneering biotechnology company founded in 1978, dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. With a robust portfolio of medicines, Biogen is a global leader in the treatment of multiple sclerosis (MS) and has introduced the first and only approved treatment for spinal muscular atrophy (SMA). The company is also at the forefront of research for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
Headquartered in Cambridge, Massachusetts, Biogen operates worldwide with research facilities in Zug, Switzerland, and state-of-the-art manufacturing plants in North Carolina and Denmark. The company employs approximately 7,000 people globally, emphasizing a collaborative and inclusive work environment.
Biogen's significant achievements include the development of revolutionary MS treatments such as Avonex, Plegridy, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for SMA and Leqembi for Alzheimer’s disease, in collaboration with partners like Ionis and Eisai respectively. Biogen continues to expand its pipeline with promising candidates currently in various stages of clinical trials.
Recent developments have seen Biogen and Eisai submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for monthly maintenance dosing of Leqembi, aimed at treating Alzheimer's disease in its early stages. Furthermore, Biogen published its 2023 Corporate Responsibility Report, highlighting its commitment to sustainable practices and social responsibility across four key pillars.
In addition to its core operations, Biogen collaborates with companies like Delta Flight Products to improve travel experiences for passengers with reduced mobility. This initiative reflects Biogen’s broader mission to enhance the quality of life for individuals facing debilitating conditions.
Biogen's financial health is robust, with strategic mergers and acquisitions like the recent purchase of Human Immunology Biosciences for $1.15 billion, aiming to bolster its immunology pipeline. The company’s comprehensive approach to business involves balancing bold scientific endeavors with prudent financial management to ensure long-term growth and shareholder value.
For more information about Biogen's latest news and updates, visit www.biogen.com.
UCB and Biogen (NASDAQ: BIIB) announced positive topline results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, for moderate-to-severe systemic lupus erythematosus (SLE). The study met its primary endpoint, demonstrating greater improvement in disease activity compared to placebo after 48 weeks. Key secondary endpoints measuring disease activity and flares also showed clinical improvements.
Based on these results, UCB and Biogen are initiating a second Phase 3 trial, PHOENYCS FLY, in 2024. The companies aim to address the substantial unmet medical need for SLE patients, particularly women who are disproportionately affected. The safety profile of dapirolizumab pegol was generally consistent with previous studies and expectations for SLE patients receiving an immunomodulator.
Biogen Inc. (Nasdaq: BIIB) has announced the appointment of two new independent directors to its Board. Dr. Lloyd Minor, Dean of Stanford University School of Medicine, will join on October 1, 2024, and Prof Sir Menelas Pangalos, former Executive VP of Biopharmaceuticals R&D at AstraZeneca, will join on January 1, 2025.
These appointments bring significant scientific expertise and experience in medicine research and development to Biogen's Board. Dr. Minor has played a key role in Stanford Medicine's strategy and leadership, while Prof Sir Pangalos has a strong track record in biopharmaceutical R&D transformation.
The Board expects these new directors to contribute fresh perspectives and deep scientific knowledge to bolster Biogen's portfolio and drive long-term, sustainable growth.
Biogen Inc. (Nasdaq: BIIB) has announced positive topline results from the Phase 2/3 DEVOTE study evaluating a higher dose regimen of nusinersen for treating spinal muscular atrophy (SMA). The study met its primary endpoint, showing statistically significant improvement in motor function compared to a matched sham control group. The new regimen comprises a more rapid loading schedule and a higher maintenance dose than the approved SPINRAZA regimen.
Key findings include:
- Significant improvement in CHOP-INTEND scores at six months
- Faster reduction in neurofilament levels, indicating slower neurodegeneration
- Generally well-tolerated safety profile
- Positive trends across secondary endpoints and key biomarkers
Biogen plans to submit for regulatory approval of this investigational higher dose regimen, aiming to address the ongoing unmet needs in SMA treatment.
Leqembi® (lecanemab) has received Marketing Authorization from the MHRA in Great Britain for treating mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients who are apolipoprotein E ε4 heterozygotes or non-carriers. This makes Great Britain the first European country to authorize this treatment targeting an underlying cause of AD.
The approval is based on Phase 3 Clarity AD clinical trial data, which showed statistically significant results in primary and key secondary endpoints. Lecanemab selectively binds to and clears toxic Aβ protofibrils from the brain. Common side effects include infusion-related reactions and ARIA.
Eisai and Biogen will co-promote Leqembi in Great Britain, with Eisai as the Marketing Authorization holder. They are working with health authorities to make the medicine available to eligible patients as soon as possible.
Alcyone Therapeutics has received FDA approval to continue enrollment in the PIERRE pivotal IDE clinical study for the ThecaFlex DRx™ System. This implantable device is being investigated for routine subcutaneous administration of nusinersen to treat spinal muscular atrophy (SMA). The first stage, involving 10 SMA patients, has been completed with no device-related adverse events. The FDA has approved enrollment of an additional 80 SMA patients across 30 centers in the U.S. and Europe.
Key observations include:
- Implantation duration: 1-2 hours
- Hospital discharge: Within 24 hours
- Infusion procedure: Less than 30 minutes
- Actual nusinersen infusion: Less than 10 minutes
The ThecaFlex system aims to provide a less invasive, more accessible alternative to repeat lumbar puncture for SMA patients receiving SPINRAZA® (nusinersen) therapy.
Eisai and Biogen presented new clinical data for LEQEMBI® (lecanemab-irmb) at AAIC 2024, showing continued benefits for early Alzheimer's disease patients after three years of treatment. Key findings include:
- 51% of patients with no/low tau showed improved cognition and function over 3 years
- Lecanemab's dual action on protofibrils and plaques slows tau spread across all brain regions
- Three years of treatment reduced clinical decline by -0.95 on CDR-SB scale
- Safety profile remained consistent with no new concerns over 3 years
- Biomarker data suggests AD continues progressing after plaque clearance, supporting continued treatment
The results indicate lecanemab provides ongoing clinically meaningful benefits for early AD patients through its unique dual mechanism targeting toxic protofibrils and plaques.
Biogen (BIIB), Beckman Coulter, and Fujirebio have announced a collaboration to develop blood-based biomarkers and tests for tau pathology in Alzheimer's disease (AD). The partnership aims to create accessible, minimally invasive tools to stratify patients and monitor treatment response for future therapies targeting tau pathology in AD.
The collaboration will leverage Biogen's expertise in biomarker research and clinical study data, while Fujirebio and Beckman Coulter will handle diagnostic development, manufacturing, and commercialization. These tau-specific blood-based biomarkers could provide critical insights into AD's pathological processes and potentially accelerate the development of new therapies.
Eisai and Biogen announced that the European Medicines Agency's CHMP has adopted a negative opinion on the Marketing Authorization Approval for lecanemab, their Alzheimer's disease (AD) treatment. This decision is a setback for the companies in the European market, where 6.9 million people are affected by AD, with numbers expected to double by 2050. Lecanemab is already approved in several countries, including the US, Japan, and China. Eisai plans to seek re-examination of the CHMP opinion to make the treatment available in the EU. The companies remain committed to addressing the unmet need in early AD treatment, emphasizing the significance of targeting underlying causes of disease progression.
Sage Therapeutics and Biogen announced disappointing topline results from their Phase 2 KINETIC 2 study of SAGE-324 (BIIB124) for treating essential tremor (ET). The study failed to demonstrate a statistically significant dose-response relationship or any significant differences between SAGE-324 doses and placebo in reducing tremor severity. Key findings include:
- No statistically significant improvements in the primary endpoint (TETRAS Performance Subscale Item 4 total score) or secondary endpoint (TETRAS Activities of Daily Living Composite Score)
- 147 participants were randomized to placebo, 15 mg, 30 mg, or 60 mg doses
- Common side effects included somnolence, dizziness, and fatigue
- Dose-related increases in CNS depressant side effects were observed
As a result, Sage and Biogen will discontinue further clinical development of SAGE-324 for essential tremor.
Biogen (Nasdaq: BIIB) has finalized its acquisition of Human Immunology Biosciences (HI-Bio), a clinical-stage biotech firm focused on targeted therapies for severe immune-mediated diseases (IMDs). This acquisition brings the promising late-stage therapeutic candidate felzartamab into Biogen’s pipeline. Felzartamab has shown positive interim results in Phase 2 trials for IgA nephropathy (IgAN) and antibody-mediated rejection (AMR), and proof-of-concept in primary membranous nephropathy (PMN). Biogen aims to advance felzartamab to Phase 3 trials for these indications, bolstering its immunology portfolio.
Key figures from both companies expressed enthusiasm about the merger, highlighting shared values and a commitment to innovative treatments for patients with unmet needs.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
What does Biogen Inc. specialize in?
Where is Biogen headquartered?
What are some of Biogen's key products?
How many employees does Biogen have?
What recent acquisitions has Biogen made?
What are Biogen’s latest research initiatives?
How is Biogen improving travel for people with mobility issues?
What is Biogen’s approach to corporate responsibility?
What is Leqembi and what is its significance?
Where can I find more information about Biogen?
